These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25760602)

  • 1. The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition.
    Yosaatmadja Y; Patterson AV; Smaill JB; Squire CJ
    Acta Crystallogr D Biol Crystallogr; 2015 Mar; 71(Pt 3):525-33. PubMed ID: 25760602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
    Liang D; Chen Q; Guo Y; Zhang T; Guo W
    Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
    Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
    Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.
    Ryan MR; Sohl CD; Luo B; Anderson KS
    Mol Cancer Res; 2019 Feb; 17(2):532-543. PubMed ID: 30257990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.
    Kas SM; de Ruiter JR; Schipper K; Schut E; Bombardelli L; Wientjens E; Drenth AP; de Korte-Grimmerink R; Mahakena S; Phillips C; Smith PD; Klarenbeek S; van de Wetering K; Berns A; Wessels LFA; Jonkers J
    Cancer Res; 2018 Oct; 78(19):5668-5679. PubMed ID: 30115694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
    Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
    Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3.
    Hwang G; Kim H; Yoon H; Song C; Lim DK; Sim T; Lee J
    Int J Nanomedicine; 2017; 12():5345-5357. PubMed ID: 28794627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.
    Rooney C; Geh C; Williams V; Heuckmann JM; Menon R; Schneider P; Al-Kadhimi K; Dymond M; Smith NR; Baker D; French T; Smith PD; Harrington EA; Barrett JC; Kilgour E
    PLoS One; 2016; 11(2):e0149628. PubMed ID: 26905262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AZD4547 Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting Inflammation: The Role of FGFR1 in Renal Tubular Epithelial Cells.
    Chen X; Zhang X; Xu J; Zhao Y; Bao J; Zheng Z; Han J
    Drug Des Devel Ther; 2020; 14():833-844. PubMed ID: 32161443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
    Paik PK; Shen R; Berger MF; Ferry D; Soria JC; Mathewson A; Rooney C; Smith NR; Cullberg M; Kilgour E; Landers D; Frewer P; Brooks N; André F
    Clin Cancer Res; 2017 Sep; 23(18):5366-5373. PubMed ID: 28615371
    [No Abstract]   [Full Text] [Related]  

  • 13. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.
    Sohl CD; Ryan MR; Luo B; Frey KM; Anderson KS
    ACS Chem Biol; 2015 May; 10(5):1319-29. PubMed ID: 25686244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure.
    Kalyukina M; Yosaatmadja Y; Middleditch MJ; Patterson AV; Smaill JB; Squire CJ
    ChemMedChem; 2019 Feb; 14(4):494-500. PubMed ID: 30600916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic suppression of a disintegrin acurhagin-C in combination with AZD4547 and reparixin on terminating development for human osteosarcoma MG-63 cell.
    Shih CH; Chiang TB; Wang WJ
    Biochem Biophys Res Commun; 2017 Oct; 492(3):513-519. PubMed ID: 28823917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMR backbone assignments of the tyrosine kinase domain of human fibroblast growth factor receptor 1.
    Vajpai N; Schott AK; Vogtherr M; Breeze AL
    Biomol NMR Assign; 2014 Apr; 8(1):85-8. PubMed ID: 23325512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.
    Qiu XH; Li F; Cao HQ; Shao JJ; Mei JG; Li HQ; Zhai YP
    Mol Med Rep; 2017 Mar; 15(3):1024-1030. PubMed ID: 28138694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
    Ren S; Rivard CJ; Yu H; Genova C; Rozenboom L; Gao D; Hinz TK; Rikke BA; Wynes MW; Caldwell C; Agustoni F; Kenichi Suda ; Jiang T; Zhou C; Heasley LE; Hirsch FR
    Clin Lung Cancer; 2018 Sep; 19(5):450-456. PubMed ID: 30146263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation.
    Morales-Guadarrama G; Méndez-Pérez EA; García-Quiroz J; Avila E; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2022 Oct; 223():106132. PubMed ID: 35659529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
    Chudasama P; Renner M; Straub M; Mughal SS; Hutter B; Kosaloglu Z; Schweßinger R; Scheffler M; Alldinger I; Schimmack S; Persigehl T; Kobe C; Jäger D; von Kalle C; Schirmacher P; Beckhaus MK; Wolf S; Heining C; Gröschel S; Wolf J; Brors B; Weichert W; Glimm H; Scholl C; Mechtersheimer G; Specht K; Fröhling S
    Clin Cancer Res; 2017 Feb; 23(4):962-973. PubMed ID: 27535980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.